A two-drug combination of Cabometyx, a once-daily pill, and Opdivo, an anti-cancer immunotherapy, improved the survival of previously untreated patients with kidney cancer compared to an older treatment, sunitinib, the companies behind the two drugs said Monday.
The study was eagerly awaited by Cabometyx’s maker, Exelixis, as its investors have fretted that the drug’s sales growth could be slowed by combinations of newer medicines and other immunotherapy treatments.
In a filing with the Securities and Exchange Commission Monday, Exelixis said that in previously untreated advanced or metastatic renal cell carcinoma, the combination reduced the risk of disease progression by 49%, and the risk of death by 40%. The study used the 40-milligram dose of Cabometyx, one of three avalable.
About the Author Reprints
